The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study

Shuichi Kitada1*, Shohei Kikuchi1, Takeshi Tsujino2, Tohru Masuyama3, Nobuyuki Ohte1 and J-MELODIC study investigators

1Department of Cardio-Renal Medicine and Hypertension, Nagoya City University, Nagoya, Japan; 2Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan; 3Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

Abstract

Aims Cardiac function varies in the population of patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF; HFpEF). This study investigated the heterogeneity of clinical features associated with HF and the prognostic value of BNP levels in patients with HFpEF.

Methods and results The study enrolled 288 patients with stable HF and serum creatinine <1.5 mg/dL who were part of the original J-MELODIC study cohort. They were categorized as having HF with reduced LVEF (HFrEF; EF ≤ 40%, n = 83) or as having HFpEF (EF > 40%, n = 205). Patients with HFpEF were further categorized as having relatively low LVEF (HFrlEF; EF 40–60%, n = 107) or as having relatively high LVEF (HFrhEF; EF ≥ 60%, n = 98). We defined cardiovascular death and hospitalization for HF as adverse events and evaluated the prognostic value of the BNP levels in each group. There was no significant difference in event-free survival between HFpEF and HFrEF patients or between HFrhEF and HFrlEF patients. A multivariate Cox proportional hazards model revealed that the BNP level was an independent predictor of adverse events in HFrEF patients (hazard ratio: 4.088, 95% confidence interval: 1.178–14.179, P = 0.027) and in HFrlEF patients (hazard ratio: 14.888, 95% confidence interval: 4.969–44.608, P < 0.001) but not in HFrhEF patients (P = 0.767).

Conclusions The BNP level has prognostic value in HFrlEF but not in HFrhEF. This indicates that HFrhEF and HFrlEF are distinct entities that may require different approaches for the management of HF.

Keywords BNP; Heart failure; Preserved LVEF; Prognosis

Received: 21 February 2017; Revised: 23 July 2017; Accepted: 26 July 2017

Introduction

Almost half of all patients with clinical features of heart failure (HF) have preserved left ventricular ejection fraction (LVEF), and the prognosis of these patients is similar to that of patients with HF and reduced LVEF (HFrEF). Although the morbidity and mortality of patients with HFrEF have improved recently, they remain unchanged in patients with HF with preserved LVEF (HFpEF).1,2 HFpEF patients are generally categorized according to their HF symptoms and according to LVEF ≥ 50%, which represents an impairment of LV diastolic function even when systolic function is normal. However, several studies in patients with HFpEF have performed detailed examinations using echocardiography and/or cardiac magnetic resonance imaging. The results demonstrated that LV systolic function is impaired in patients with much higher LVEF levels than LVEF 50%.3–5 In addition, we previously reported loss of inertia force of late systolic aortic flow (IFLAF), which was obtained by using a catheter-tipped micromanometer in cardiac catheterization, as a predictor of development of HF in patients with preserved LVEF.6 The existence of IFLAF is strongly dependent on LV systolic function.
function and through which LV relaxation is speeded.\textsuperscript{7} Our previous findings demonstrated that the patients having less than 58% of LVEF could lose IFLAF even though they had preserved LVEF (>50%).\textsuperscript{8} Thus, we hypothesized that patients who are commonly categorized into HFrEF may not be uniform in the clinical features associated with HF as well as in their cardiac function.

Brain natriuretic peptide (BNP) is secreted primarily from cardiac myocytes in response to changes in LV wall stress, and it acts to promote myocyte stretch. BNP levels are associated with HF severity and are a reliable predictor of prognosis throughout the stages of HF.\textsuperscript{9–11} In addition, recent reports show that elevated BNP levels are associated with poor prognosis in patients with HFrEF as well as in those with HFrEF.\textsuperscript{12,13} Accordingly, the current study investigated the heterogeneity of clinical features associated with HF and the prognostic value of BNP levels in patients with HFrEF. The study patients were derived from the cohort of the Japanese Multicenter Evaluation of Long- vs. short-acting Diuretics In Congestive heart failure (J-MELODIC) trial. In addition, the correlations between the BNP levels and measured values of IFLAF were evaluated in another cohort as a supplemental analysis.

## Methods

### Study population and data collection

The J-MELODIC study was a multicentre, prospective, randomized, open, and blinded endpoint trial in Japan that compared the effect of long-term administration of azosemide, a long-acting loop diuretic, to that of furosemide, a short-acting diuretic, on the prognosis of patients with chronic HF. The trial design and main findings were published previously.\textsuperscript{14,15} The study, which ran from June 2006 to August 2008, enrolled 320 patients using the following inclusion and exclusion criteria. The inclusion criteria were age 20 years or older, a clinical diagnosis of HF based on a slight modification of the Framingham criteria\textsuperscript{16} within 6 months before study entry, New York Heart Association functional class II or III symptoms, loop diuretic(s) use, and no changes in baseline drug therapy or in HF symptoms within 1 month prior to enrolment. The exclusion criteria were uncontrolled diabetes mellitus or hypertension, serum creatinine (sCr) > 2.5 mg/dL, acute coronary syndrome, an implantable cardiac defibrillator, haemodynamically significant LV outflow tract obstruction, acute myocardial infarction within the past 3 months, percutaneous coronary intervention or open heart surgery within the past 3 months, any changes in cardiovascular drug therapy within a month prior to randomization (such as the requirement of intravenous inotropes), and/or any serious non-cardiovascular disease, including malignancy. We analysed 288 patients from the J-MELODIC study cohort after excluding 32 patients who had severe renal dysfunction with sCr ≥ 1.5 mg/dL. We used the demographic, laboratory, and echocardiographic data at enrolment and the outcome data from the J-MELODIC study. The study endpoint was a composite of unplanned hospital admission due to acute decompensated HF and cardiovascular death. Cardiovascular death was defined in the J-MEDOLIC study as death from worsening of congestive HF, coronary artery disease, cardiac arrest, cardiac arrhythmia, myocardial infarction, stroke, or sudden death.

### Study design

In this study, the patient population was divided into two groups: patients with HFrEF (LVEF ≤ 40%; the HFrEF group) and patients with HFrEF (LVEF > 40%; the HFrEF group). Patients with HFrEF were further divided into two subgroups using 60% LVEF as a cut-off value. This is because we found previously that LVEF ≥ 60% was associated with the maintenance of IFLAF in patients with HFrEF. The IFLAF is a notable systolic functional parameter with predictive value for adverse events in HFrEF and is calculated from the LV pressure and the dp/dt relationship.\textsuperscript{6–8} One subgroup consisted of patients with HF with relatively high LVEF (LVEF ≥ 60%; the HFrhEF group), and the other subgroup consisted of patients with relatively low LVEF (40% < LVEF < 60%; the HFrIF group). This study compared the clinical backgrounds and outcomes in the HFrEF, HFrhEF, and HFrIF groups. It also compared the impact of BNP levels on the prognosis of the patients in each study group.

This sub-analysis of the J-MELODIC study was conducted in full accordance with the Declaration of Helsinki, and it received approval from the Institutional Review Boards and Ethics Committees at all sites. The supplemental study was also performed in full accordance with the Declaration of Helsinki, and it received approval from the Institutional Review Boards of Nagoya City University Hospital, Japan.

### Supplemental analysis

We conducted a supplemental analysis to clarify the pathophysiological background of the difference in the impact of BNP levels on the prognosis of patients with HFrEF between the HFrhEF and HFrIF groups. A total of 428 patients, who received a catheterization study using a catheter-tipped micromanometer to evaluate a coronary artery disease and demonstrated LVEF > 40% in left ventriculography in our institution (Nagoya City University Hospital, Japan) from April 2001 to December 2010, were enrolled in this analysis. We analysed the data of patients’ clinical backgrounds including BNP and LVEF levels. In addition, from the recorded LV pressure waves, we computed the IFLAF from the LV pressure and
dP/dt relationship (phase loop) based on the theoretical basis, which was previously reported by Sugawara et al. We divided the study patients into two subgroups; patients with rhEF (LVEF ≥ 60%) and those with rHEF (40% < LVEF < 60%). The correlations between the BNP levels and measured values of IFLAF were evaluated in the whole study patients and in these two subgroups.

**Statistical analysis**

Continuous data are presented as means ± standard deviation or medians (with 25th and 75th percentiles). To compare variables, the Student’s unpaired t-test or Mann–Whitney U test was used between two groups and one-way analysis of variance with Tukey test or Kruskal–Wallis test was used among three groups. Categorical variables are summarized as frequencies and percentages and were compared using Pearson’s χ² test or Fisher’s exact test. A P-value < 0.05 was considered statistically significant. A Cox proportional hazards model was used to evaluate the contributions of the clinical variables and log BNP levels to the relative hazard of experiencing the composite terminal adverse events. The model was adjusted for age, sex, azosemid use, and for selected variables that showed a significant association (P < 0.1) with adverse events in the univariate analysis. For the prognosis analysis, the observation period was the time from enrolment to the occurrence of a terminal adverse event or to the last censoring time point at which the patients had survived without adverse events during the follow-up period. Cumulative event-free survival was calculated with Kaplan–Meier product limit estimators. Survival curves were compared among the groups using a log-rank test. The Pearson correlation coefficient is used to measure the strength of a linear association between the BNP levels and measured values of IFLAF. The tightness of correlation of cardiac performance.

**Table 1 Characteristics of patients (n = 288) with heart failure**

|                      | HFrEF (n = 83) | Total (n = 205) | HFrEF (n = 107) | HFrhEF (n = 98) |
|----------------------|---------------|----------------|----------------|----------------|
| Age, years           | 67.1 ± 11.9   | 72.4 ± 10.1 a  | 70.1 ± 11.0 a  | 75.0 ± 8.3 a b |
| Female, n (%)        | 18 (21.7)     | 113 (55.1) a  | 39 (36.4) a    | 53 (54.1) a b  |
| BMI, kg/m²            | 22.7 ± 3.7    | 23.6 ± 4.6     | 24.0 ± 4.6     | 23.2 ± 4.7     |
| Systolic BP, mmHg     | 117 ± 19      | 126 ± 16 a     | 126 ± 15 a     | 130 ± 16 a     |
| Heart rate, beats/min| 71 ± 14       | 71 ± 13        | 71 ± 13        | 71 ± 14        |
| Ischaemic heart disease, n (%) | 39 (47.0) | 52 (25.4) a    | 37 (34.6) a    | 15 (15.3) a b  |
| NYHA class II/III, n (%) | 72/11 (86.7/13.3) | 186/19 (90.8/9.2) | 98/9 (91.6/8.4) | 88/10 (89.8/10.2) |
| Sodium, mmol/L        | 139.6 ± 1.6   | 140.4 ± 2.8 a  | 140.3 ± 2.9    | 140.5 ± 2.8    |
| Potassium, mmol/L     | 4.3 ± 0.4     | 4.3 ± 0.4      | 4.3 ± 0.5      | 4.3 ± 0.4      |
| Haemoglobin, g/dL     | 13.2 ± 1.6    | 12.7 ± 2.0 a   | 13.0 ± 1.9     | 12.3 ± 2.0 a b |
| eGFR, mL/min/1.73m²   | 60.5 ± 18.0   | 55.5 ± 15.7 a  | 56.5 ± 17.0    | 54.4 ± 14.1 a  |
| BNP, pg/mL            | 137.0 (68.0, 348.5) | 105.4 (47.7, 237.6) a | 109.0 (52.7, 266.9) | 100.0 (47.5, 212.0) a |
| Log BNP, pg/mL        | 2.152 ± 0.540 | 1.985 ± 0.511 a | 2.000 ± 0.550  | 1.970 ± 0.467  |
| Comorbidities, n (%)  |              |                |                |                |
| Atrial fibrillation/flutter | 15 (18.1)  | 87 (42.4) a    | 41 (38.3) a    | 46 (46.9) a    |
| Hypertension          | 44 (53.0)     | 138 (67.3) a   | 69 (64.5)      | 69 (70.4)      |
| Diabetes              | 25 (30.1)     | 65 (31.7)      | 33 (30.8)      | 32 (32.7)      |
| Myocardial infarction  | 42 (50.6)     | 45 (22.0) a    | 35 (32.7) a    | 10 (10.2) a b  |
| Stroke                | 6 (7.2)       | 32 (15.6)      | 13 (12.1)      | 19 (19.4)      |
| Echocardiographic findings |            |                |                |                |
| LVEF, %               | 32.9 ± 6.1    | 58.8 ± 10.4 a  | 50.4 ± 5.5 a   | 67.9 ± 5.7 a b |
| LVEDD, mm             | 60.6 ± 8.1    | 51.7 ± 7.8 a   | 54.5 ± 7.8 a   | 48.6 ± 6.5 a b |
| IVST, mm              | 8.7 ± 2.1     | 10.2 ± 2.3 a   | 9.9 ± 2.3 a    | 10.5 ± 2.4 a   |
| LAD, mm               | 43.0 ± 8.1    | 45.4 ± 8.6 a   | 45.1 ± 8.3     | 45.6 ± 8.9     |
| IVC, mm               | 13.8 ± 4.0    | 15.7 ± 4.5 a   | 15.2 ± 4.4     | 16.1 ± 4.7 a   |
| E/A                   | 1.15 ± 0.88   | 0.91 ± 0.64    | 0.97 ± 0.75    | 0.84 ± 0.43    |
| Medication for HF, n (%) |           |                |                |                |
| ACE-I and/or ARB      | 66 (79.5)     | 142 (69.3)     | 79 (73.8)      | 63 (64.3)      |
| Beta-blocker          | 65 (78.3)     | 84 (41.0) a    | 55 (51.4) a    | 29 (29.6) a b  |
| Aldosterone blocker   | 45 (54.2)     | 74 (36.1) a    | 43 (40.2) a    | 31 (31.6) a    |
| Azosemid              | 42 (50.6)     | 98 (47.8)      | 55 (51.4)      | 43 (43.9)      |

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; eGFR, estimated glomerular filtration rate; E/A, ratio of E to A wave velocity of transmitral flow; HF, heart failure; HFrEF, heart failure with preserved ejection fraction; HFrhEF, heart failure with relatively high ejection fraction; HFrEF, heart failure with relatively low ejection fraction; IVC, inferior vena cava; IVST, interventricular septal thickness; LAD, left atrial dimension; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NYHA class, New York Heart Association classification of cardiac performance.

*aSignificant difference compared with the HFrEF group.

*bSignificant difference between the HFrEF and HFrhEF groups.

DOI: 10.1002/ehf2.12206
of association between the rhEF and rlEF groups was compared using Fisher’s z-test for Pearson correlations in the supplemental analysis. All statistical analyses were performed with SPSS version 23.0 software (SPSS Japan Inc., Tokyo).

Results

Patient characteristics

Of a total of 320 patients in the J-MELODIC study, 288 patients were enrolled in the current study, including 83 patients with HFrEF (28.8%) and 205 patients with HFpEF (71.2%). About half of the patients with HFpEF were patients with HFrEF (n = 107, 52.2%), and the rest were patients with HFrEF (n = 98, 47.8%). The patient characteristics at the time of enrolment are summarized in Table 1. Compared with patients in the HFrEF group, those in the HFpEF group were older, more frequently female, and more frequently had atrial fibrillation and/or flutter and hypertension; these patients less frequently had ischaemic heart disease as the aetiology of HF. The BNP levels of the HFpEF group were significantly lower than those of the HFrEF group. Comparisons of the clinical backgrounds of the HFrEF and HFrlEF groups demonstrated that patients in the HFrEF group were older and more frequently female but that they less frequently had ischaemic heart disease as the aetiology of HF and less frequently used β-blockers. The BNP levels did not differ significantly between the HFrEF and HFrlEF groups; however, the haemoglobin level was significantly lower in the HFrEF group than in the HFrlEF group (12.3 ± 2.0 vs. 13.9 ± 1.9 g/dL, P < 0.05).

Event-free survival

There were 11 cardiovascular deaths and 42 hospitalisations for HF during the follow-up period [median follow-up period: 1045.5 days (25th and 75th percentiles: 797.5 and 1230.0, respectively)]. There were 2 cardiovascular deaths and 15 hospitalisations for HF in the HFrEF groups [median follow-up period: 1092.0 days (25th and 75th percentiles: 784.0 and 1297.5, respectively)], and there were 9 cardiovascular deaths and 27 hospitalisations in the HFpEF group [median follow-up period: 1016.0 days (25th and 75th percentiles: 802.0 and 1194.0, respectively)].

We compared the cumulative adverse event-free survival curves between the HFrEF and the HFpEF groups. There was no significant difference in event-free survival between the two groups (P = 0.642; Figure 1A). Furthermore, the HFrlEF group had 5 cardiovascular deaths and 19 hospitalisations for HF [median follow-up period: 985.0 days (25th and 75th percentiles: 781.5 and 1194.0, respectively)] and the HFrEF group had 4 cardiovascular deaths and 8 hospitalisations for HF [median follow-up period: 1054.0 days (25th and 75th percentiles: 844.0 and 1194.0, respectively)].

Figure 1 (A) Comparison of adverse event-free survival curves of patients with heart failure with reduced ejection fraction (HFrEF; blue line) vs. patients with heart failure with preserved ejection fraction (HFpEF; red line). Event-free survival was not significantly different in the two groups. (B) Comparison of adverse event-free survival curves in patients with HFrEF (blue line), with heart failure and relatively low ejection fraction (HFrlEF; red line), and with heart failure and relatively high ejection fraction (HFrlEF; dashed red line). Event-free survival was not significantly different in these three groups.
Prognostic value of BNP

Table 2 shows the prognostic value of the BNP levels in each group. In the HFrEF group, a multivariate Cox proportional hazards model revealed that the log BNP level was a significant independent predictor of adverse events [hazard ratio (HR): 4.088, 95% confidence interval (CI): 1.178 to 14.179, \( P = 0.027 \)] after adjusting for age, sex, azosemide use, and selected variables with significance in the univariate analysis, such as haemoglobin level, LVEF, and estimated glomerular filtration rate. Similarly, in the HFrhEF group, a multivariate Cox proportional hazards model revealed that the log BNP level was a significant independent predictor of adverse events (HR: 0.701, 95% CI: 0.572 to 0.859, \( P = 0.001 \)).

In contrast, in the HFrhEF group, a univariate Cox proportional hazards model revealed that age and serum sodium concentration were significantly associated with terminal adverse events, but the BNP level was not (\( P = 0.668 \)). A multivariate Cox proportional hazards model revealed that serum sodium concentration was a significant independent predictor of adverse events after adjusting for age, sex, LVEF, and selected variables with significance in the univariate analysis, such as azosemide use.

Correlation between the BNP levels and measured values of inertia force of late systolic aortic flow

The patient characteristics of the supplemental analysis were shown in Table 3. Compared with the patients with rHEF, the patients with rLEF were significantly younger, less frequently of female sex, had significantly lower systolic blood pressure, higher BNP levels, and lower measured values of IFLAF. In addition, hyperlipidaemia was less frequently seen, and past histories of both myocardial infarction and HF were more frequently seen in the patients with rLEF. A significant negative correlation between the BNP levels and measured values of IFLAF was observed (\( r = -0.319, P < 0.001 \)) in whole study patients (Figure 2). The tightness of such a correlation was significantly lower in the patients with rHEF (\( r = -0.228, P < 0.001 \)) than in those with rLEF (\( r = -0.345, P < 0.001 \)) (Fisher’s z-test for Pearson correlation, \( P < 0.001 \)) (Figure 3).

Discussion

There were four main findings from this study. (i) Half of the patients with HfPEF showed LVEF \( \geq 60\% \). These patients were older and more frequently female, but they less frequently had ischaemic heart disease as the aetiology for HF compared with patients with HfPEF and LVEF < 60%. (ii) There was no significant difference in event-free survival between patients with HFrEF and those with HFrLEF. (iii) The BNP levels demonstrated significant prognostic value for adverse events in patients with HFrEF but not in patients with HFrhEF. (iv) Low serum sodium levels were related to adverse events in patients with HFrEF.

Ageing, female sex, hypertension, and atrial fibrillation are risk factors for readmission and for disease pathogenesis in HfPEF. In addition, myocardial infarction is reported to be less associated with disease pathogenesis in HfPEF than in HFrEF.\(^{17,18}\) In the current study, a comparison of the characteristics of the patients in the HfPEF and HFrEF groups revealed a tendency that was in accordance with previous reports. Specifically, we found that the characteristics of patients in the HFrhEF and HFrEF groups were less similar than the characteristics of the HFrLEF and HFrEF groups. Ueda et al.\(^{19}\) demonstrated that patients with HfPEF and LVEF >55% were significantly less likely to have ischaemic heart disease as an aetiology of HF compared with those with HF and 50% < LVEF \( \leq 55\% \). This is consistent with the results in our study. In addition, Ueda et al.\(^{19}\) concluded that LVEF >55% in patients with HfPEF (LVEF > 50%) was significantly associated with a decrease in LVEF to below 50% during a mean follow-up period of 31.5 \( \pm \) 17.0 months. They suggested that patients with HF and preserved but relatively low LVEF (50% < LVEF \( \leq 55\% \)) were distinct (in terms of HF) from those with HF and relatively high LVEF (LVEF > 55%) in a group of patients with HfPEF based on the aetiology of HfPEF. In contrast, we demonstrated that patients with HF and preserved but relatively low LVEF (40% < LVEF < 60%) were pathophysiologically dissimilar to those with HF and relatively high LVEF (LVEF \( \geq 60\% \)) based on the aforementioned findings indicating that the LVEF 60% was a crucial value to determine the importance of BNP level as a predictor of future HfPEF.

We reported previously that a loss of IFLAF, which was calculated from the LV pressure and dP/dt relationship as derived from LV pressure waves obtained with a catheter-tipped micromanometer,\(^7\) was significantly associated with adverse events in HF among patients with preserved LVEF (LVEF \( \geq 50\% \)).\(^{5,8}\) The loss of IFLAF is highly associated with...
|                  | HFrEF Univariate |          |          | HFrEF Multivariate |          |          | HFpEF Univariate |          |          | HFpEF Multivariate |          |          | HFrlEF Univariate |          |          | HFrlEF Multivariate |          |          | HFrhEF Univariate |          |          | HFrhEF Multivariate |
|------------------|------------------|----------|----------|-------------------|----------|----------|------------------|----------|----------|-------------------|----------|----------|------------------|----------|----------|-------------------|----------|----------|-------------------|----------|----------|-------------------|----------|
|                  | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value HR (95% CI) | P value |
| Log BNP, pg/mL   | 0.002 4.088 (1.17–14.17) | <0.001 4.632 (2.15–9.96) | <0.001 14.888 (4.96–44.60) | 0.668 | 0.767 |
| Age, years       | 0.010 0.864 | 0.165 0.867 | 0.369 0.711 | 0.015 1.164 (1.03–1.31) | 0.012 |
| Female sex       | 0.574 0.215 | 0.252 0.196 | 0.720 0.861 | 0.347 | 0.377 |
| BMI              | 0.189 0.325 | 0.154 0.455 | 0.619 0.948 | 0.538 | 0.217 |
| Systolic BP, mmHg| 0.368 0.442 | 0.209 0.349 | 0.421 | 0.015 | 0.701 (0.57–0.85) |
| LVEF, %          | 0.036 0.119 | 0.051 0.959 (0.92–0.99) | 0.020 0.530 | 0.585 | 0.613 |
| eGFR, ml/min/1.72m² | 0.002 0.929 (0.87–0.985) | 0.014 0.929 (0.87–0.985) | 0.014 0.929 (0.87–0.985) | 0.014 0.929 (0.87–0.985) | 0.150 |
| Beta-blocker     | 0.351 0.126 | 0.126 | 0.791 |
| ACE-I/ARB        | 0.856 0.984 | 0.261 | 0.106 |
| Azosemide        | 0.684 0.164 | 0.058 0.479 (0.23–0.98) | 0.046 0.371 | 0.042 | 0.392 |

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HR, hazard ratio; HR, heart rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFrhEF, heart failure with relatively high ejection fraction; HFrlEF, heart failure with relatively low ejection fraction; LVEF, left ventricular ejection fraction; Na, sodium.
the impairment of LV relaxation because of a lack of elastic recoil at the very early phase of diastole.\textsuperscript{7,17,20} We also demonstrated previously that LVEF < 58\% could significantly predict the loss of inertia force in patients with preserved LVEF.\textsuperscript{8} In addition, several other studies that used Doppler echocardiography or cardiac magnetic resonance have reported the impairment of systolic function in patients with LVEF levels that are much higher than 50\% (up to around 60\%) of LVEF in patients with preserved LVEF.\textsuperscript{6-8} Therefore, in this study, we divided the patients with HFrEF into two subgroups using 60\% of LVEF as a cut-off value in order to investigate differences in clinical features associated with HF in these two subgroups.

Previous data indicated that HFrEF morbidity and mortality were similar to HFrEF morbidity and mortality. Whereas survival in HFrEF has improved over the last decade, it remains unchanged, or has even worsened, in HFrEF. In addition, there are no medical treatments that convincingly improve the outcome in HFrEF.\textsuperscript{1,21,22} In the current study, the adverse event-free survival of patients with HFRF was similar to that of patients with HFrEF. That is consistent with previous reports. Furthermore, we found that there was a tendency for event-free survival to be better in patients with HFrEF compared with those with HFRF among patients with HFrEF; however, this trend did not reach statistical significance ($P = 0.067$). Good systolic function of LV is observed in patients with high LVEF and should speed LV relaxation, which overcomes a substantial risk of development of HF associated with LV diastolic dysfunction.\textsuperscript{6,7,20} This result suggests that maintaining higher LVEF in HF might improve prognosis.\textsuperscript{23}

Plasma BNP level is reported to be a reliable predictor of poor outcome not only in HFrEF but also in HFrEF.\textsuperscript{12,13} BNP is secreted primarily by cardiac myocytes in response to increase in LV wall stress, resulting in myocyte stretch, and the BNP level shows good correlation with LV end-diastolic pressure. BNP levels are associated with HF severity across the spectrum of HF stages.\textsuperscript{9-11} In the current study, the BNP levels showed a significantly independent predictive value for poor prognosis in patients with HFrEF, HFrEF, and HFRF. In contrast, the BNP levels of patients with HFRF were not significantly associated with adverse events. This suggests that the BNP level loses its prognostic value in HFRF while maintaining prognostic value in HFRF. It further suggests that HFrEF and HFrEF are, to some extent, distinct entities in HFrEF that require different approaches to evaluate the HF status.
Our supplemental analysis demonstrated a significant negative correlation between BNP levels and measured values of IFLAF ($r = -0.319$, $P < 0.001$) in patients with preserved LVEF. Goto et al. reported the importance of IFLAF as a prognostic indicator in patients with preserved LVEF. Furthermore, when the tightness of correlation was compared between patients with rEF and those with rhEF, such a correlation would become significantly lower in the patients with rhEF ($r = -0.228$, $P < 0.001$) compared with those with rEF ($r = -0.345$, $P < 0.001$). The attenuation of tightness of correlation between BNP levels and measured values of IFLAF in patients with LVEF ≥ 60% compared with those LVEF < 60% may be associated with a decrease in prognostic value of BNP levels in patients with HFrhEF.

Notably, a multivariate Cox proportional hazards model revealed that hyponatraemia was significantly associated with adverse events in patients with HFrhEF. In a recent report, Kusaka et al. demonstrated that the serum sodium level was independently correlated with future HF-related events in HFrEF. The authors concluded that pathophysiological conditions were different in HF patients with vs. without hyponatraemia. Here, we found that hyponatraemia was associated with adverse events in patients with HFrhEF, which is consistent with the report of Kusaka et al. Hyponatraemia is an electrolyte abnormality that is commonly observed in patients with HF and that indicates poor prognosis in HF. Fluctuations in the serum sodium concentration are regulated through the secretion of antidiuretic hormone (ADH), and the increased ADH secretion in HF induces water retention in renal tubules, resulting in hypervolemic hyponatraemia. Activation of the ADH axis, which is a predominant neurohormonal activation in the pathogenesis of HF, is observed in patients with HFP EF as well as in those with HFrEF. Hyponatraemia may be associated with worsening of HFrhEF through the mechanism that causes increased ADH secretion in HF.

This study had several limitations. First, our study was a retrospective analysis of data from the J-MELODIC study. The J-MELODIC study cohort showed stable HF, and the participants received loop diuretic therapy. Therefore, we only analysed patients who required loop diuretic therapy for their HF symptoms. Second, we investigated a small cohort that had a limited number of adverse events. To strengthen our conclusion, a prospective study is needed that has a larger study cohort and that includes patients with HF who are not receiving loop diuretics therapy for HF. Finally, we did not address any changes in LVEF during the course of each patient’s illness, and we did not investigate the association between changes in LVEF and prognosis.

In conclusion, the differences in clinical characteristics and in the relationships between the BNP levels and prognostic value for adverse events indicate that HFrhEF (LVEF ≥ 60%) and HFrEF (40% < LVEF < 60%) have some distinct clinical and pathophysiological characteristics even though both are categorized as HFP EF.

Conflict of interest

None declared.

Funding

The J-MELODIC study was supported by a grant from the Ministry of Health, Labor and Welfare, Japan [H18-Junkankitou (Seishuu)-Ippan-046] and by a grant from the Japan Heart Foundation.
References

1. Bharia RS, Tu JV, Lee DS, Austin PC, Fang J, Hauzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260–269.

2. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Get with the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65–75.

3. Garcia EH, Perna ER, Farías EF, Goto T, Wakami K, Fukuta H, Fujita H, Magosaki N, Niki K, Jones CJ, Sugimachi T, Sase K, Kihara Y, Goto Y, Nonogi H. Lack of inertia force of left ventricle in vivo? J Am Coll Cardiol 2016; 68: 1498–1506.

4. van Veldhuisen DJ, Linsen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HIL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61: 1498–1506.

5. Kaku K, Takeuchi M, Otani K, Sugeng L, Nakai H, Haruki N, Yoshitani H, Watanabe N, Yoshida K, Otsumi Y, Moravi V, Lang RM. Age- and gender-dependency of left ventricular geometry assessed with real-time three-dimensional transthoracic echocardiography. J Am Soc Echocardiogr 2011; 24: 541–547.

6. Yoshida T, Otte N, Narita H, Sakata S, Wakami N, Kasada K, Miyabe H, Saeki T, Kikura G. Lack of inertia force of late systolic aortic flow is a cause of left ventricular isolated diastolic dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2006; 48: 983–991.

7. Sugawara M, Uchida K, Konodoh Y, Magsaki N, Niki K, Jones CJ, Sugimachi M, Sunagawa K. Aortic blood momentum—the more the better for the ejection heart in vivo? Cardiovasc Res 1997; 33: 433–446.

8. Goto T, Wakami K, Fukuta H, Fujita H, Tani T, Otte N. Patients with left ventricular ejection fraction greater than 58% have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. Heart Vessels 2016; 31: 734–743.

9. Doust JA, Pietrzak E, Dobson A, Glasziou P. CardioMEMS and B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.

10. Iwana Y, Nishi I, Furuchi S, Noguchi T, Sise K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Am Coll Cardiol 2006; 47: 742–748.

11. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missow ED, Clerico A, Tognoni G, Cohn JN, Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in heart failure patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528–1538.

12. van Veldhuisen DJ, Linsen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HIL. ProBNP in heart failure with preserved versus reduced EF. Heart 2015; 101: 1881–1888.

13. J-MELODIC Program Committee. Rationale and design of a randomized trial to assess the effects of diuretics in heart failure: Final Evaluation of Long- vs Short-Acting Diuretics in Congestive Heart Failure (J-MELODIC). Circ J 2007; 71: 1137–1140.

14. Masuyama T, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, Otte N, Daimon T, Nakatani S, Itô H. Sup ervision of the Japan Society of Cardiac Registry of Heart Failure patients in the treatment of congestive heart failure. J Am Coll Cardiol 2012; 76: 833–842.

15. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441–1445.

16. Tsuchihashi-Makaya M, Hamaguchi S, Yamamoto K, Akiyama E, Matsuzawa Y, Hirata Y, Fujise K, Kurokawa H, Matsubara J, Sugamura K, Maeda H, Jinnouchi H, Matsu K, Ogawa H. Low-normal serum sodium and heart failure-related events in patients with heart failure with preserved left ventricular ejection fraction. JACC Heart Fail 2016; 4: 502–510.

17. Kusaka H, Sugiyama S, Yamamoto E, Akiyama E, Matsuuzawa Y, Hirata Y, Fujise K, Kurokawa H, Matsubara J, Sugamura K, Maeda H, Jinnouchi H, Matsu K, Ogawa H. Long- vs Short-Acting Diuretics in Heart Failure (Val-HeFT) data. J Am Coll Cardiol 2006; 48: 983–991.

18. Kusaka H, Sugiyama S, Yamamoto E, Akiyama E, Matsuuzawa Y, Hirata Y, Fujise K, Kurokawa H, Matsubara J, Sugamura K, Maeda H, Jinnouchi H, Matsu K, Ogawa H. Low-normal serum sodium and heart failure-related events in patients with heart failure with preserved left ventricular ejection fraction. J Am Coll Cardiol 2006; 48: 983–991.

19. Rossi J, Bayram M, Udelson JE, Lloyd-Jones D, Adams KF, O'Connor CM, Stough WG, Ouyang J, Shin DD, Orlandi C, Gheorghiade M. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Care Card 2007; 9: 82–86.

20. Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M. Hyponatremia in heart failure. Heart Fail Rev 2009; 14: 59–63.

21. Goldsmith SR, Cowley AW Jr, Francis GS, Cohn JN. Reflex control of osmotically stimulated vasopressin in normal humans. Am J Physiol 1985; 248:65:R660–R663.

22. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure. ESC Heart Fail 2018; 5: 36–45 DOI: 10.1002/ehf2.12206
failure: a review of the literature. *Expert Opin Pharmacother* 2011; **12**: 961–976.

29. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. *Ann Intern Med* 1984; **101**: 370–377.

30. Hage C, Lund LH, Donal E, Daubert JC, Linde C, Mellbin L. Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. *Open Heart* 2015; **2**: e000260.

31. Kitada S, Kikuchi S, Sonoda H, Yoshida A, Ohse N. Elevation of arginine vasopressin levels following loop diuretic therapy as a prognostic indicator in heart failure. *J Int Med Res* 2016; **44**: 1430–1442.